Literature DB >> 17121780

Rapidly progressive renal failure associated with successful pharmacotherapy for obesity.

Aisling E Courtney1, Declan M O'Rourke, Alexander Peter Maxwell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17121780     DOI： 10.1093/ndt/gfl684

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN： 0931-0509            Impact factor:   5.992


× No keyword cloud information.
  10 in total

1.  Evidence of Misclassification of Drug-Event Associations Classified as Gold Standard 'Negative Controls' by the Observational Medical Outcomes Partnership (OMOP).

Authors:  Manfred Hauben; Jeffrey K Aronson; Robin E Ferner
Journal:  Drug Saf       Date:  2016-05       Impact factor: 5.606

Review 2.  Orlistat-associated adverse effects and drug interactions: a critical review.

Authors:  Theodosios D Filippatos; Christos S Derdemezis; Irene F Gazi; Eleni S Nakou; Dimitri P Mikhailidis; Moses S Elisaf
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 3.  Obesity: Current and potential pharmacotherapeutics and targets.

Authors:  Vidya Narayanaswami; Linda P Dwoskin
Journal:  Pharmacol Ther       Date:  2016-10-20       Impact factor: 12.310

Review 4.  Does orlistat cause acute kidney injury?

Authors:  Michael M Beyea; Amit X Garg; Matthew A Weir
Journal:  Ther Adv Drug Saf       Date:  2012-04

Review 5.  Benefit-risk assessment of orlistat in the treatment of obesity.

Authors:  Priya Sumithran; Joseph Proietto
Journal:  Drug Saf       Date:  2014-08       Impact factor: 5.606

6.  Orlistat-induced oxalate nephropathy: an under-recognised cause of chronic kidney disease.

Authors:  Laurence Richard Solomon; Andrew Christopher Nixon; Leanne Ogden; Beena Nair
Journal:  BMJ Case Rep       Date:  2017-11-12

Review 7.  Current issues in the management and monitoring of hypertension in chronic kidney disease.

Authors:  Pranav S Garimella; Katrin Uhlig
Journal:  Curr Opin Nephrol Hypertens       Date:  2013-11       Impact factor: 2.894

Review 8.  Impact of treating the metabolic syndrome on chronic kidney disease.

Authors:  Varun Agrawal; Aashish Shah; Casey Rice; Barry A Franklin; Peter A McCullough
Journal:  Nat Rev Nephrol       Date:  2009-07-28       Impact factor: 28.314

9.  Furosemide, orlistat and non-steroidal anti-inflammatory agents-too much for the kidneys to handle!

Authors:  Asher Korzets; Uzi Gafter; Ana Tobar; Avri Chagnac; Boris Zingerman; Yaacov Ori
Journal:  NDT Plus       Date:  2009-01-26

10.  Secondary Oxalate Nephropathy: A Systematic Review.

Authors:  Nuttha Lumlertgul; Monchai Siribamrungwong; Bertrand L Jaber; Paweena Susantitaphong
Journal:  Kidney Int Rep       Date:  2018-07-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.